The standard for the wire, not the device
Section 514(b) of the FD&C Act lets FDA write a performance standard directly into the Code of Federal Regulations — binding by rule, not by the voluntary declaration-of-conformity track FDA revises twice a year. One example has stood since 1997: 21 CFR Part 898, keyed not to a product code or device type but to the lead wires and patient cables connecting a device to a patient.
By Connor Griggs — Regulatory & Quality Strategist
Most of what a device file calls “the standard” is voluntary until FDA recognizes it: cite an edition from the Recognized Consensus Standards Database, attach a declaration of conformity, and the submission gets the benefit without anyone being legally required to build to that specific document. Section 514(b) of the FD&C Act describes a different, far less used power — FDA writing a performance standard directly into the Code of Federal Regulations, binding on its own terms, with no declaration format and no list revised twice a year. One example has stood since 1997, and it doesn’t name a device at all.
A standard issued by rule, not by recognition
21 CFR Part 898, Performance Standard for Electrode Lead Wires and Patient Cables, was finalized by Federal Register notice on May 9, 1997, under docket 94N-0078, and took effect that August. FDA built it under Section 514(b) — 21 U.S.C. 360d(b) — the subsection that lets the agency establish a performance standard by notice-and-comment rulemaking for a device type FDA determines needs one. That is a different track from 514(c), the mechanism that merely recognizes a standard someone else wrote. Part 898 is one of the small number of device performance standards FDA has actually finished through the 514(b) route rather than the recognition list.
Keyed to a connector, not a product code
The regulation’s applicability section, 898.11, reaches any electrode lead wire or patient cable intended for use with a medical device — language with no product code and no device class attached to confine it to one kind of equipment. The actual requirement, 898.12, is narrower and specific: any connector in the cable or lead wire with a conductive connection to a patient has to meet subclause 56.3(c) of IEC 601-1 (1988), as amended in 1991 and 1995 — the clause aimed at stopping a patient-connected pin from also being able to carry line voltage. FDA’s own 1999 guidance on applying the rule to electrosurgical devices had to work out, lead type by lead type, which of an electrosurgical unit’s active and dispersive electrode leads the standard reaches, because 898.11’s own wording doesn’t settle that by device type at all.
The standard doesn’t ask what device you’re building. It asks what the wire touches.
The practice
A declaration-of-conformity table built from the Recognized Consensus Standards Database will never surface 898.12, because it isn’t a recognized standard a filer declares conformity to — it is the regulation itself, and it won’t appear on a list revised twice a year because it was never on that list to begin with. A device with any lead wire or patient cable carrying a conductive connection to a patient needs that applicability question answered directly against Part 898’s own text, independent of whatever consensus-standards table the rest of the submission’s test reports are organized around. This is regulatory intelligence about where one binding requirement lives in the CFR, never advice about whether a specific cable or connector design meets it.
Primary sources
- eCFR — 21 CFR Part 898, Performance Standard for Electrode Lead Wires and Patient Cables
- Federal Register — Performance Standard for Electrode Lead Wires and Patient Cables (final rule, May 9, 1997)
- 21 U.S.C. § 360d(b) — Performance standards (FD&C Act § 514(b))
- FDA — Electrosurgical Devices and Application of the Performance Standard for Electrode Lead Wires and Patient Cables (guidance)
Regulatory intelligence, not regulatory advice. This post describes method and published FDA records as of its date; decisions about a specific device belong with your regulatory professional.